Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

被引：11

作者：

Hizal, Mutlu ^{[1
]}

Sendur, Mehmet A. N. ^{[1
]}

Yasar, Hatime Arzu ^{[2
,3
]}

Bir Yucel, Kadriye ^{[4
]}

Arslan, Cagatay ^{[5
]}

Ucar, Gokhan ^{[6
]}

Karakaya, Serdar ^{[7
]}

Taban, Hakan ^{[8
]}

Kucukarda, Ahmet ^{[9
]}

Erturk, Ismail ^{[10
]}

Bilgin, Burak ^{[1
]}

Yildirim, Nuriye ^{[11
]}

Demirci, Umut ^{[7
]}

Kilickap, Saadettin ^{[8
]}

Cicin, Irfan ^{[9
]}

Karadurmus, Nuri ^{[10
]}

Yalcin, Bulent ^{[1
]}

Urun, Yuksel ^{[2
,3
]}

机构：

[1] Yildirim Beyazit Univ, Dept Med Oncol, Fac Med, Ankara, Turkey

[2] Ankara Univ, Sch Med, Dept Med Oncol, Ankara, Turkey

[3] Ankara Univ, Canc Res Inst, Ankara, Turkey

[4] Ankara Univ, Fac Med, Dept Internal Med, Ankara, Turkey

[5] Bahcesehir Univ, Fac Med, Dept Internal Med & Med Oncol, Istanbul, Turkey

[6] Univ Hlth Sci, Ankara Numune Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey

[7] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Ankara Oncol Educ & Res, Dept Med Oncol, Ankara, Turkey

[8] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[9] Trakya Univ, Dept Med Oncol, Fac Med, Edirne, Turkey

[10] Univ Hlth Sci, Gulhane Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey

[11] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2020年 / 26卷 / 07期

关键词：

Interferon; neutrophil-lymphocyte ratio; prognosis; renal cell cancer; tyrosine kinase inhibitors; PRETREATMENT NEUTROPHIL; INFLAMMATION; CANCER; IMPACT; PROGRESSION; VALIDATION;

D O I：

10.1177/1078155219900908

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background To describe the prognostic value of neutrophil-lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. Methods We retrospectively analyzed 331 patients. The cut-off value of neutrophil-lymphocyte ratio was specified as "3" which is mostly close-and also clinically easily applicable-to the median neutrophil-lymphocyte ratio level of our study group. High group is identified as neutrophil-lymphocyte ratio >3 (n = 160) and low group is identified as neutrophil-lymphocyte ratio <= 3 (n = 163). Results A total of 331 (with 211 male and 120 female) patients were enrolled to study. The median age of the patients was 58. The International Metastatic RCC Database Consortium risk score is calculated for the 72.8% (n = 241) of the study group and among these patients, favorable, intermediate, and poor risk rates were 22, 45.2, and 32.8%. The total usage of tyrosine kinase inhibitors reached 78% of the patients. The median overall survival was 32 months versus 11 months in the neutrophil-lymphocyte ratio low and high groups, respectively (HR: 0.49 (95% CI 0.37-0.65), p < 0.001). Conclusion In conclusion, the pre-treatment value of elevated neutrophil-lymphocyte ratio might be a predictor of poor overall survival in advanced renal cell carcinoma patients.

引用

页码：1583 / 1589

页数：7

共 32 条

[1] Akinci Ozyurek Berna, 2017, Asian Pac J Cancer Prev, V18, P1417
[2] Signatures of mutational processes in human cancer
Alexandrov, Ludmil B.
Nik-Zainal, Serena
Wedge, David C.
Aparicio, Samuel A. J. R.
Behjati, Sam
Biankin, Andrew V.
Bignell, Graham R.
Bolli, Niccolo
Borg, Ake
Borresen-Dale, Anne-Lise
Boyault, Sandrine
Burkhardt, Birgit
Butler, Adam P.
Caldas, Carlos
Davies, Helen R.
Desmedt, Christine
Eils, Roland
Eyfjord, Jorunn Erla
Foekens, John A.
Greaves, Mel
Hosoda, Fumie
Hutter, Barbara
Ilicic, Tomislav
Imbeaud, Sandrine
Imielinsk, Marcin
Jaeger, Natalie
Jones, David T. W.
Jones, David
Knappskog, Stian
Kool, Marcel
Lakhani, Sunil R.
Lopez-Otin, Carlos
Martin, Sancha
Munshi, Nikhil C.
Nakamura, Hiromi
Northcott, Paul A.
Pajic, Marina
Papaemmanuil, Elli
Paradiso, Angelo
Pearson, John V.
Puente, Xose S.
Raine, Keiran
Ramakrishna, Manasa
Richardson, Andrea L.
Richter, Julia
Rosenstiel, Philip
Schlesner, Matthias
Schumacher, Ton N.
Span, Paul N.
Teague, Jon W.
[J]. NATURE, 2013, 500 (7463) : 415 - +
[3] [Anonymous], 2019, J CLIN ONCOL S
[4] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
Asaoka, Tadafumi
Miyamoto, Atsushi
Maeda, Sakae
Tsujie, Masanori
Hama, Naoki
Yamamoto, Kazuyoshi
Miyake, Masakazu
Haraguchi, Naotsugu
Nishikawa, Kazuhiro
Hirao, Motohiro
Ikeda, Masataka
Sekimoto, Mitsugu
Nakamori, Shoji
[J]. PANCREATOLOGY, 2016, 16 (03) : 434 - 440
[5] Inflammation and cancer: back to Virchow?
Balkwill, F
Mantovani, A
[J]. LANCET, 2001, 357 (9255) : 539 - 545
[6] Landmarks in the diagnosis and treatment of renal cell carcinoma
Bhatt, Jaimin R.
Finelli, Antonio
[J]. NATURE REVIEWS UROLOGY, 2014, 11 (09) : 517 - 525
[7] The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review
Boissier, Romain
Campagna, Jennifer
Branger, Nicolas
Karsenty, Gilles
Lechevallier, Eric
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) : 135 - 141
[8] Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer
Chen, Jie
Deng, Qiwen
Pan, Yuqin
He, Bangshun
Ying, Houqun
Sun, Huiling
Liu, Xian
Wang, Shukui
[J]. FEBS OPEN BIO, 2015, 5 : 502 - 507
[9] The Role of Inflammation in Kidney Cancer
Chevez, Antonio Roma de Vivar
Finke, James
Bukowski, Ronald
[J]. INFLAMMATION AND CANCER, 2014, 816 : 197 - 234
[10] Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
Cho, HanByoul
Hur, Hye Won
Kim, Sang Wun
Kim, Sung Hoon
Kim, Jae Hoon
Kim, Young Tae
Lee, Kook
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 15 - 23

← 1 2 3 4 →